PARTNERSHIPS

Galenea has demonstrated commitment to building relationships and forming alliances with pharmaceutical and biotechnology companies and academic institutions, with the goal of taking innovative products to the clinic.

Current Partnerships

Galenea forged a multi-year R&D collaboration with Otsuka Pharmaceutical Co., Ltd. based on the calcineurin pathway and its role in schizophrenia pathogenesis. This partnership, established to generate breakthrough treatments for schizophrenia and related disorders, was extended and expanded in 2008 based on significant advances in several of the collaborative projects.

Galenea has an exclusive worldwide license to indole-based 5-HT2C agonists discovered by Organix and its academic collaborators. Organix is working with Galenea to advance these compounds into the clinic for the treatment of obesity and other CNS diseases.

New Partnerships

Galenea intends to continue to build its pipeline through internal programs and additional partnerships. We are actively seeking to license, acquire or co-develop early-stage small molecule product candidates that can be advanced by leveraging our predictive tools, behavioral models and medicinal chemistry expertise.

For more information, please contact our Head of Corporate Development at: CorpDev@galenea.com